コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ntaining the cDNA for LL-37/hCAP-18, a human cathelicidin antimicrobial peptide.
2 ability of PilB to mediate GBS resistance to cathelicidin antimicrobial peptides.
3 ate immune responses, such as the release of cathelicidin antimicrobial peptides.
4 deI and ompD are important for resistance to cathelicidin antimicrobial peptide, a mouse AMP produced
11 r Typhi and S. Typhimurium will induce human cathelicidin antimicrobial peptide (CAMP) production, an
12 (S1P), regulates production of a major AMP, cathelicidin antimicrobial peptide (CAMP), in response t
15 or (VDR)-dependent mechanisms regulate human cathelicidin antimicrobial peptide (CAMP)/LL-37 in vario
17 ction was mediated through the production of cathelicidin antimicrobial peptide from adipocytes becau
20 The genes encoding lysozyme, lactoferrin, cathelicidin antimicrobial peptide (hCAP18/LL-37), cathe
23 h AD, but not psoriasis, is deficient in the cathelicidin antimicrobial peptide (LL-37) and human bet
24 esponding to residues 7-27 of the only human cathelicidin antimicrobial peptide, LL37, is shown to ex
25 These observations provide evidence that cathelicidin antimicrobial peptides mediate an anti-infl
26 mycin, the susceptibility of the bacteria to cathelicidin antimicrobial peptides or serum complement
29 , organelles that also contain precursors of cathelicidins, antimicrobial peptides that undergo prote
31 Using MCs derived from mice deficient in cathelicidin antimicrobial peptide, we showed that antim
32 tibility to reactive oxygen species and host cathelicidin antimicrobial peptides, which correlated wi
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。